"Recurrence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The return of a sign, symptom, or disease after a remission.
| Descriptor ID |
D012008
|
| MeSH Number(s) |
C23.550.291.937
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recurrence".
Below are MeSH descriptors whose meaning is more specific than "Recurrence".
This graph shows the total number of publications written about "Recurrence" by people in this website by year, and whether "Recurrence" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 15 | 15 |
| 1998 | 0 | 19 | 19 |
| 1999 | 0 | 16 | 16 |
| 2000 | 0 | 11 | 11 |
| 2001 | 0 | 14 | 14 |
| 2002 | 0 | 21 | 21 |
| 2003 | 0 | 24 | 24 |
| 2004 | 0 | 28 | 28 |
| 2005 | 0 | 17 | 17 |
| 2006 | 0 | 31 | 31 |
| 2007 | 0 | 30 | 30 |
| 2008 | 0 | 30 | 30 |
| 2009 | 0 | 21 | 21 |
| 2010 | 0 | 35 | 35 |
| 2011 | 0 | 41 | 41 |
| 2012 | 0 | 27 | 27 |
| 2013 | 0 | 43 | 43 |
| 2014 | 0 | 38 | 38 |
| 2015 | 0 | 41 | 41 |
| 2016 | 0 | 39 | 39 |
| 2017 | 0 | 46 | 46 |
| 2018 | 0 | 50 | 50 |
| 2019 | 0 | 51 | 51 |
| 2020 | 0 | 45 | 45 |
| 2021 | 0 | 41 | 41 |
| 2022 | 0 | 26 | 26 |
| 2023 | 0 | 31 | 31 |
| 2024 | 13 | 14 | 27 |
| 2025 | 0 | 33 | 33 |
| 2026 | 0 | 19 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recurrence" by people in Profiles.
-
Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 Jul 28; 10(14):5087-5096.
-
Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 Jul 14; 10(13):4776-4785.
-
Surgical Excision Versus Percutaneous Ultrasound-Guided Fenestration for Pediatric Ganglia: A Cost and Recurrence Rate Analysis. J Am Acad Orthop Surg. 2026 Aug 01; 34(15):e2092-e2096.
-
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review. Blood Adv. 2026 May 26; 10(10):3467-3479.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
Wound healing, wound-free period and amputation-free survival in patients with Wound, Ischemia, and foot Infection (WIfI) stage 3 and 4 disease. J Vasc Surg. 2026 Aug; 84(2):459-470.e2.
-
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant. 2026 May; 61(5):591-600.
-
MRI of pediatric meniscal retears following primary arthroscopic surgery: diagnostic accuracy and common findings. Skeletal Radiol. 2026 Jul; 55(7):1627-1637.
-
Statin Use and Recurrent Atherosclerotic Cardiovascular Disease Events in Patients With Coronary Artery Intervention: A Retrospective Analysis From a Large Health Care Network. J Am Heart Assoc. 2026 Mar 17; 15(6):e041416.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.